Roche (SIX:ROG; OTCQX:RHHBY) announced in its 3Q18 earnings it discontinued development of five new molecular entities, including Phase II rheumatoid arthritis candidate RG6125 (SDP051), plus two programs in development for follow-on indications. The pharma lost...

Roche (SIX:ROG; OTCQX:RHHBY) announced in its 3Q18 earnings it discontinued development of five new molecular entities, including Phase II rheumatoid arthritis candidate RG6125 (SDP051), plus two programs in development for follow-on indications. The pharma lost...

TECHNOLOGY: SNPs SNPs on 30 genomic loci could help predict the risk of schizophrenia. Genome-wide association studies in 47,559 schizophrenia patients and 70,936 healthy volunteers identified associations between the disease and SNPs on 30 loci,...

Roche will acquire Adheron, a developer of technology that disrupts cell adhesion via cell surface protein cadherin 11 ( Cad-11 ; CDH11 ). Adheron is investigating therapies for inflammatory and autoimmune disorders, including rheumatoid arthritis and...

Roche (SIX:ROG; OTCQX:RHHBY) will acquire Adheron Therapeutics Inc. (Berkeley, Calif.), a developer of technology that disrupts cell adhesion via cell surface protein Cadherin 11 ( Cad-11 ; CDH11 ). Adheron is investigating therapies for inflammatory and...

A newly discovered pathway that causes joint erosion in rheumatoid arthritis could lead to a new class of therapies that act locally in cells of the synovial lining and avoid the drawbacks of immunosuppressants. The...

A placebo-controlled Phase I trial in healthy volunteers showed that single ascending-doses of SDP051 were well tolerated up to 10 mg/kg with no evidence of significant adverse events. Next year, Adheron plans to start a...